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The past decade saw the advent of a number of promising biomarkers to detect
pregnancies at risk for preeclampsia (PE), the foremost being those associated with an
imbalance of angiogenic factors. In late pregnancy, these are useful for the detection of
imminent cases of PE, while earlier they were more predictive for early- than late-onset PE.
This suggests that there may be fundamental differences between the underlying
pathology of these two PE forms. Therefore, it is possible that such a biological premise
may limit the development of biomarkers that will permit the efficacious detection of both
early- and late-onset PE via an analysis of first-trimester maternal blood samples.
Consequently, a significant increase in our understanding of the underlying pathology of
PE, using a variety of approaches ranging from systems biology to animal models, will be
necessary in order to overcome this obstacle.
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It has recently been suggested that a concerted
effort should be undertaken to invert the pyra-
mid of prenatal care [1]. In this manner, more
emphasis would be placed on the early detec-
tion of pregnancy complications, such as
preeclampsia (PE), preterm labor (PTL), intra-
uterine fetal growth restriction (IUGR) or fetal
genetic anomalies such as Down syndrome
(DS) in the first, rather than in the second or
third trimester of pregnancy [1,2].
The rationale behind such a proposed para-
digm shift is the observation that it may be
possible to extend the scope of the current
first trimester integrated or combined test,
conducted at 11–13 weeks of gestation, to
detect not only fetal chromosomal anomalies,
but also pregnancies at risk for an array of
complications including PE, IUGR and
PTL [1,2].
Such a practice would effectively break with
a nearly century-old tradition. It would also
lead to a change in therapeutic strategy,
namely the long-term intervention or amelio-
ration rather than the fait accompli of severe
manifest symptoms clinicians are currently pre-
sented with, frequently leaving no other option
than emergency delivery of a very premature
baby. Hence, in this new first trimester screen-
ing setting, at-risk pregnancies would pursue a
separate path of dedicated specialist care, while
normal low-risk pregnancies would undergo
standard routine examinations in the second
and third trimester as per usual [1].
The success of such a scheme would depend
on the detection rate of at-risk pregnancies, and
possible therapeutic options, that is, if only a
fraction could be detected and no treatment
option existed, then what would be the point? [3].
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PE – syndrome with multiple etiologies?
PE is a relatively frequent disorder of pregnancy, affecting
between 3 and 8% of all pregnant women, with a higher pre-
disposition for certain ethnic groups [4–8]. It is characterized by
a sudden elevation in blood pressure (BP) in previously normo-
tensive pregnant women, a feature accompanied by proteinuria
and frequently edema [4–7]. If left untreated, PE can progress to
eclampsia, characterized by epileptic-like seizures. This condi-
tion is frequently fatal, especially in developing countries, where
mortality rates may be as high as 15% [4–7,9].
Despite best clinical practice in developed countries, PE
remains a leading cause of fetal and maternal morbidity and
mortality, especially with regard to preterm delivery [6,10].
The clinical presentation of PE can be confusing and need
not follow the general pattern of elevated BP followed by pro-
teinuria, but can occur in a reverse order or with obscured clin-
ical symptoms [9,11]. Furthermore, the advent of eclampsia can
be sudden, without noticeable signs of PE, and may even occur
very early in the second trimester [9]. An additional confound-
ing condition is that PE can occur postpartum, by a period as
late as 3 weeks [9,12]. These cases are frequently severe, and can
be associated with maternal mortality [12].
For this reason, the pathophysiology leading to the develop-
ment of PE has been deemed so complex that PE has fre-
quently been labeled a disease of theories [13–15]. This facet has
changed significantly in the past decade when a significant
understanding in the underlying etiology was gained [7]. These
include the imbalance in angiogenic factors [16], the contribu-
tion by placental galectin PP13 (placental protein 13) [17], the
activation of the complement cascade [18] and the excessive
presence of neutrophil extracellular traps (NETs) directly in the
intervillous space of affected placentae [19,20].
Further immunological factors suggested to play a role in PE
include reduced expression of the tolerance molecule HLA-G
on the trophoblast [21], inappropriate action of uterine NK
cells [22], an imbalance in Treg [23], reduced placental expression
of the tryptophan catabolizing enzyme indoleamine 2,3-dioxy-
genase (IDO) [24], altered distribution of placental macro-
phages [25] or occurrence of autoantibodies against the type 1
angiotensin II receptor [26] as well as thrombin and platelet
activation [27].
PE – two forms depending on time of onset?
A fundamental contribution to our understanding was the seg-
regation of PE into early (<34 weeks gestation, ePE) and late-
onset forms (>34 weeks gestation, lPE), with the implication
that these two forms may be disparate and the result of differ-
ent or independent lesions [8,28]. This tenet is supported by a
number of lines of evidence, including differences in placental
pathology between ePE and lPE [29], the association of ePE but
not lPE with certain genetic loci such as the activin A receptor
IIA [30], or evidence of ischemic stress and endoplasmic reticu-
lum stress-induced apoptosis in ePE placentae [31,32].
On the other hand, lPE appears to be associated with factors
which are not directly placenta associated and not evident in
ePE, such as reduced levels of 25-hydroxyvitamin D [33] or
ficolin-2, a carbohydrate pattern recognition receptor [34]. Addi-
tionally, the incidence of lPE but not ePE, may be enhanced
by certain environmental factors, such as air pollution or espe-
cially obesity [35,36].
A further noteworthy factor to bear in mind is that the inci-
dence of lPE is almost 10-fold higher than that of ePE [37,38],
and although the symptoms for the former may be less severe
than for the latter, they are still of considerable clinical con-
cern, especially in tertiary settings [39].
Following almost century-old reports of familial clusters of
PE [40], a considerable effort has been made to determine
genetic factors that contribute to the development of PE [41],
which has resulted in the detailing of almost 180 genetic
loci [42]. Although currently no clear data exist concerning
genetic predisposition for ePE rather than lPE or vice-versa,
epidemiological data indicate that pre-existing chronic hyper-
tension appears to be a significant risk factor for the develop-
ment of ePE, rather than lPE [38].
Differences also appear to exist on the postpartum influence
of ePE or lPE on mother and child. In this context, data from
a recent study indicate that ePE is associated with a signifi-
cantly higher occurrence of postpartum cardiovascular disor-
ders, such as hypertension, than lPE [43].
Furthermore, ePE leads to an increased risk of childhood
asthma, not evident in the children born from lPE pregnan-
cies [44]. The issue of ePE or lPE can also lead to confusion, as
is evident from studies testing the efficacy of low-dose aspirin,
where some studies indicate that this can reduce the incidence
of lPE [45], while more recent data suggest that this may be
more useful for cases at risk of ePE [46].
These diverse facets suggesting different underlying etiologies
are explored in more detail below and referred to in FIGURE 1.
Development of PE – a dual role of the placenta?
While it is generally accepted that the placenta is the main cul-
prit triggering the development of PE, it is still unclear what
exact contribution in each instance it has [7,29,47]. In this regard,
the placenta in ePE is frequently characterized by inadequate
modification of the maternal spiral arteries by invasive fetal
cytotrophoblast cells [29].
During early embryo development, the placenta has limited
contact to the maternal circulation since the mouths of the
maternal spiral arteries are plugged by invading trophoblast
cells [48]. These relatively hypoxic conditions are suggested to
protect the fetus from potential teratogenic effects of reactive
oxygen species [49]. It is of interest to note that this condition
does not lead to hypoxic or metabolic stress in these placental
tissues, suggesting adequate nutrition and support by the
maternal endometrial glands during this phase of fetoplacental
development [50].
At the end of the first trimester these plugs are removed,
leading to a sudden exposure of the hypoxic placenta to mater-
nal circulation and to a threefold rise in oxygen concentra-
tion [49]. Aberrancies during this crucial phase of development,
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resulting in toxic oxygen levels due to too rapid or uncoordi-
nated opening of these plugs can lead to fetal loss [48].
During the second trimester, the maternal spiral arteries are
widened by the action of endovascular cytotrophoblast cells,
which replace the maternal endothelial cells [51]. This results in
a low-pressure system whereby the placental villi are bathed in
a continuous slow flow of maternal blood. A number of studies
have indicated that this modification during this crucial phase
of placenta development is defective in PE [51]. The underlying
mechanism for this defect is not clear, but may involve an inca-
pacity of the extravillous trophoblast cells to differentiate cor-
rectly [52], or it may result from the failure of the maternal
endothelial glands not producing critical cytokines in the
required amounts [48].
This feature is, however, also present in IUGR pregnancies,
and in a proportion of cases with PTL. In the latter instance,
the degree of spiral artery modification is significantly lower
than in PE or IUGR. This has led to the premise that the
major obstetrical concerns may have similar defects in deep
placentation [29].
On the other hand, recent evidence suggests that placental
lesions consistent with maternal underperfusion and spiral
artery anomalies are less frequent in cases with lPE than ePE,
but that these are still significantly more prevalent in lPE than
in healthy controls at term [53,54].
Due to the decreased incidence of these lesions in cases with
lPE, it was proposed that maternal systemic inflammation and
other factors may play more substantial roles besides placental
lesions in the development of this form of
PE. The conundrum is that both forms of
PE have similar clinical characteristics
with regard to BP and proteinuria, reflect-
ing the ‘common pathway’ of PE [53,54].
Although the placenta in lPE may
more frequently appear healthy and nor-
mal, there are other lines of evidence sug-
gesting that it may be altered in other
ways. The first of these relies on a
century-old observation that trophoblast
deportation is elevated in cases with PE,
in that trophoblast cells could be detected
in the lungs of women who had died
from eclampsia [55], a feature recently
confirmed by the detection of transcrip-
tionally active placenta fragments [56].
An examination of cross-placental fetal
cell traffic indicated that this was elevated
in cases with manifest PE [57]. Further-
more, enhanced fetal cell trafficking was
observed early in gestation prior to the
onset of symptoms [58]. As these study
cohorts included both cases with ePE and
lPE, this would suggest that the lesion
permitting cross-placental trafficking
occurs in both forms [59].
A further suggestion that the placenta is affected in both
forms of PE is provided by the quantitative analysis of placen-
tal cell-free DNA (cfDNA), where elevations in both forms
were noted [60,61]. As this material is largely released by the syn-
cytiotrophoblast (STB), this would suggest that turnover of this
tissue is dysregulated in both forms [59]. Of interest is that the
levels of placental cfDNA were greater in ePE cases than those
with lPE, despite the latter having a significantly larger pla-
centa. This indicates that the placental lesions in ePE leading
to the liberation of cfDNA are more severe [60].
In addition, it was observed that placental cfDNA levels
were elevated in cases at risk for PE well in advance of the
development of symptoms, indicating that the disturbance of
the trophoblast involved in cfDNA release is an early event in
the development of PE [62,63]. This underscores the hypothesis
that PE is a disorder of early implantation or placentation,
with a long asymptomatic phase, before these anomalies culmi-
nate in the clinical symptoms [9,59].
To account for this disparity, a model has recently been pro-
posed with two different placental causes leading to the develop-
ment of PE, with placental oxidative stress playing a central role [9].
In the development of ePE, placental oxidative stress is
mediated via the failure to adequately modify the maternal
spiral arteries, whereas in lPE, it is suggested to result predomi-
nantly as a consequence of abnormal uteroplacental perfu-
sion [9]. It is, however, possible that lPE may result from a
number of other biological or environmental stresses, especially
secondary inflammatory lesions, as indicated in FIGURE 1.
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Figure 1. Illustration of putative differences in the underlying etiology of ePE
versus lPE. The primary lesion in deep placentation plays a leading role in the develop-
ment of ePE. Failure of spiral artery modification may involve aberrant maternal inflam-
mation due to reduced PP13 expression. By leading to placental insufficiency, this results
in the liberation of inflammatory trophoblast micro-debris and imbalance in pro- and
anti-angiogenic factors, events which precede clinical symptoms. In lPE, the placental
lesion is insufficient to trigger development of clinical symptoms, bur rather renders the
maternal system highly susceptible to secondary signals, such as obesity, which then
initiate the etiological cascade leading to onset of symptoms.
ePE: Early preeclampsia; lPE: Late preeclampsia.
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As a consequence of such stress conditions, the STB produ-
ces an excess of the anti-angiogenic factor soluble fms-like tyro-
sine kinase-1 (sFlt-1), which leads to a concomitant decrease in
pro-angiogenic placental growth factor (PlGF) in maternal
blood. This imbalance in pro- and anti-angiogenic factors has
been shown to be a major contributor to the widespread sys-
temic endothelial damage evident in cases with PE [16].
It is interesting that recent studies examining placental stress
pathways in PE found that ePE is characterized by the signifi-
cant activation of stress kinase pathways, while similar phenom-
enon was not observed in lPE [32,64]. These data suggest that
factors other than those related to oxidative stress may be key
in the activation of the common pathway and angiogenic
imbalance in lPE.
PE – the role of the innate immune system
PE involves more than an imbalance in angiogenic factors, and is
for instance characterized by an excessive activation of the mater-
nal innate immune system, specifically neutrophils [65]. Indeed,
the degree of neutrophil activation assessed via the production of
reactive oxygen species was greater in PE than in cases with sep-
sis [66]. This activation is mediated via the excessive release of
microparticles by STB, and are hence, termed STBM [67].
Previous studies have indicated that STBM can trigger the
release of NETs by isolated neutrophils, and that high numbers
of NETs can be detected directly in the intervillous space of
affected placentae [19]. Since NETs can promote coagulation,
acting as a scaffold for the coagulation process [68], the excessive
presence of these structures could lead to maternal underperfu-
sion and consequent placental occlusion or infarction [20].
These would contribute to hypoxic and/or ischemic conditions
frequently detected in PE placentae [48].
In addition to neutrophils, PE is also associated with overt
activation of the complement system, as is evident by the ready
detection of complement products such as C5a and C4a in
maternal plasma, or C5b-9 and adipsin (complement factor D)
in maternal urine [18,69,70]. Activation of the complement system
was shown to occur in affected placentae, for instance, by stain-
ing for C4d deposition, which was rarely observed in normal
placentae, while it was frequently detected on the STB of PE
placentae [71]. Furthermore, PE was associated with increased
expression of CD55 and CD59, two complement regulatory
proteins [70]. In a more recent study, this aspect has been exam-
ined in more detail in both cases with ePE and lPE, where it
was observed that C1q deposition was greater in the former
than in the latter [71]. The authors also noted that maternal
C4 deficiencies were more frequent in the ePE group [71].
Mutations in the complement C3F gene are associated with an
increased susceptibility for PE [72]. Further evidence implicating
a role for complement activation in PE is the report that treat-
ment of a patient with severe ePE/HELLP syndrome with ecu-
lizumab, a targeted inhibitor of complement protein C5, which
resulted in a significant reduction of symptoms and permitted
a prolongation of pregnancy by 17 days, in itself is a remark-
able achievement [73].
Most of these findings support that the activation of the
complement pathway in the second half of pregnancy plays a
role in the development of PE. Interestingly, a prospective
study showed that women with high levels of complement acti-
vation fragment Bb before 20 weeks of gestation had increased
risk to develop PE later in pregnancy [74]. This finding suggests
that the alternative pathway of complement was activated in
these patients in early pregnancy. Moreover, studies on pen-
traxin 3 (PTX3), a multifunctional pattern recognition receptor
that also binds to complement component C1q and modulates
complement activation [75], revealed that patients who presented
with PE had higher maternal plasma levels of PTX3 than con-
trols [76,77], and maternal plasma PTX3 concentrations at 11–
13 weeks were already higher in patients subsequently develop-
ing ePE but not lPE [78,79]. These findings point to an innate
immune imbalance in the development of PE, especially ePE,
in early pregnancy.
Incidence of ePE versus lPE – the influence of secondary
inflammatory stimuli such as air pollution, diabetes or
obesity & possible lack of scavenger molecules
It is highly probable that the large number of anecdotes con-
cerning possible etiological or risk factors for PE contributed to
this enigmatic disorder being stigmatized as ‘disease of theo-
ries’ [14]. Of these is the increased incidence of PE with certain
weather conditions.
Credible evidence for such a phenomenon was provided in a
study conducted in Zimbabwe, where a seasonal influence on
the incidence of PE was noted, in that there was a peak at the
onset of the rainy season [80]. In Cape Town, at the tip of
South Africa, increased numbers of cases with PE were noted
in winter [81]. In an extended study of almost 5000 pregnant
women, of whom almost half were affected by PE, an increased
incidence was noted in autumn [82].
Unfortunately, in none of these studies was an attempt made
to stratify cases with PE into those with early or late onset.
However, it is to be assumed that a large proportion of these
were cases with lPE. Although it is unclear what the seasonal
noxin was triggering this increased onset of PE, it is possible
that it is related to air pollution, since the rural population in
South Africa rely on the burning of biofuels for heating in win-
ter. Such a facet is supported by a number of studies suggesting
that high levels of air pollutants are associated with elevations
in the incidence of PE [35,83]. In a large-scale analysis of more
than 8000 pregnant women, it was noted that exposure air-
borne particulate matter in the first trimester led to an increase
in the incidence of cases with ePE, while similar exposure in
the third trimester was associated with an increase in the num-
ber of lPE cases [84]. In a smaller scale study, exposure to air-
borne particulate matter during a particularly dusty dry
autumn was shown to be associated with an increase in the
number of lPE cases [85]. On a similar note, smoking during
pregnancy was shown to be a major risk factor for the develop-
ment of both ePE and lPE [38]. In this context, it is worth not-
ing that previous studies suggesting that smoking may appear
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protective or diminish the incidence of PE are misleading due
to left truncation bias in the statistical analysis [86].
Another set of well-described risk factors for PE are diabetes,
obesity or chronic hypertension [6,7,36,38]. In an examination of
diabetes-associated markers in ePE and lPE cases, it was deter-
mined that lPE was associated with a significant increase in insu-
lin resistance and reduced serum adiponectin concentrations [87].
These data indicated that adiponectin levels were reduced in the
first trimester in cases that developed IPE compared to ePE. In
the third trimester, adiponectin levels were only elevated in cases
that developed IPE. Therefore, these data provide further evi-
dence for an etiological difference between ePE and IPE [87,88].
The influence of obesity on the development of PE was
clearly demonstrated in a retrospective analysis of over one mil-
lion live births, where a striking association with the increasing
BMI and the incidence of lPE was noted [36]. In this regard,
super obesity having a BMI >50 was shown to be associated
with a greater than fourfold increase in lPE [36]. No significant
influence of obesity on the presence of ePE was detected [36].
A possible explanation for this increased susceptibility to sec-
ondary inflammatory stimuli may be a reduction in suitable scav-
enger molecules, such as anti-oxidant selenoproteins in PE, which
play an important role in the removal of hydroperoxides and oxi-
dized lipoproteins [89]. This hypothesis is supported by recent data
indicating that PE is associated with decreased levels of a1-micro-
globulin (A1M), crucial for the removal of radicals and heme and
furthermore, that treatment with A1M infusions can reduced PE
symptoms in a large animal model [90,91]. Consequently, the use
of A1M is being explored for the treatment of human cases with
PE, which if successful would indeed be a novel development in
the clinic [92]. It, however, remains to be seen if this therapy will
be useful for both cases with ePE and lPE, or only for the latter.
In this context, a recent large-scale study concerning folic
acid supplementation of over 10,000 pregnant women indi-
cated that while this did lead to a reduction in PE, it was most
pronounced for cases with mild or lPE [93].
Taken together, these data support the hypothesis that the
development of ePE is primarily driven by an underlying pla-
cental lesion with negligible influence from environmental or
secondary inflammatory stimuli, whereas in lPE the contribu-
tion by the placenta is not as pronounced, but the maternal
immune system has become more sensitive to secondary
inflammatory stimuli (FIGURE 1).
PP13 – only a biomarker or a crucial factor involved in
placenta development?
Similar to the above findings, several studies conducted in the
first trimester have shown that maternal blood concentrations
of the immunoregulatory PP13 are changed in PE [17,94]. Some
of these revealed that PP13 concentrations were lower in ePE
compared with controls, while this change was not significant
in lPE [95–97]. Of interest, PP13 is a uniquely placental
expressed protein, predominantly produced by the STB during
differentiation and syncytialization, from where it is released
into the maternal circulation [98–100]. Thus, decreased maternal
blood PP13 concentrations reflect decreased syncytiotrophoblas-
tic PP13 production and impaired syncytialization [98–100].
Indeed, a study that examined villous trophoblastic cells laser-
captured from first trimester CVS samples found the downre-
gulation of PP13 mRNA expression in samples from women
who later developed PE compared with normal pregnant
women [101]. All these data point to impaired early placentation
events in PE, especially in cases with early onset.
In this context, it is interesting that PP13 is member of the
multifunctional galectin family that regulates innate and adap-
tive immune responses and confer immune tolerance [17,98].
Functional studies have shown that PP13 may also have impor-
tant regulatory role on both arms of the immune system, as it
induced the apoptosis of activated T cells [98] and the cytokine
production of macrophages in vitro [102]. In addition, according
to the in situ observations of the latter study, perivenous aggre-
gates of PP13 formed in the decidua in the first trimester may
facilitate trophoblast invasion and spiral artery conversion via
attracting, activating and killing maternal immune cells. These
findings are also important from an evolutionary aspect, since
the gene encoding PP13 – along with related galectin genes in
a cluster on chromosome 19 – has emerged in anthropoid pri-
mates, species with deep placentation and long gestation [98].
Further studies need to address the immunobiological questions
on how PP13 regulates maternal-fetal immune interactions dur-
ing early placentation, and how these processes are impaired in
various PE subforms by various disease etiologies.
Multiple independent or linked etiologies – what are
the implications for biomarker development?
A caveat of the above findings is that PE could be the result of
multiple etiological factors. Such a facet was suggested by a
recent murine-human translational proteomic study, which sug-
gested three independent diverging pathways [103]. The first
group included dysfunctions in angiogenesis, the second group
included changes in MAPK signaling, while the last group
showed evidence for metabolic or hormonal changes. Of inter-
est is that GNA12, a guanine nucleotide binding protein
detected in subgroup 2, was overexpressed in PE placentae that
were coincident with chronic hypertension [103]. Although
highly detailed, no evidence for activation of the maternal
immune system was noted in this study.
In order to gain insight into possible differences between the
two PE forms, Chaiworapongsa et al. examined the maternal
blood leukocyte transcriptional signature in 25 cases with ePE,
47 with lPE in comparison with 61 uncomplicated pregnan-
cies [104]. This study showed that 43 genes were differentially
expressed between ePE and controls, versus 28 between lPE
and controls. The expression of 20 genes involved in coagula-
tion, immune regulation and inflammation was enhanced only
in ePE, while only 7 genes were altered in lPE. The expression
of 13 genes was determined to be altered in both PE forms in
comparison with controls [104].
In a similar microarray examination of maternal lympho-
cytes, a different pattern was noted between PE cases and
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controls, mainly related to complement and protein transla-
tion [105]. When the PE cases were stratified into severe ePE
and non-severe lPE, eight genes were found to be specifically
upregulated in the former. It is of interest that in both studies,
V-set and Ig domain-containing 4, related to the B7 family of
co-stimulatory molecules, showed the clearest discrimination
between ePE and lPE [105]. Apart from the above gene tran-
script findings, there is, however, additional evidence suggesting
that the underlying etiological pathways may converge into a
single mechanism initiating the maternal symptoms. These
include recent observations that urinary excretion of comple-
ment factors is associated with an imbalance in angiogenic fac-
tors in cases with severe PE [106].
A tentative link between the complement system and neutro-
phil activation has been proposed via the action of C5a, which
would further underscore a convergence of pathways [107].
These diverse findings raise the question of whether a
biomarker-based screen would detect both PE forms equally
well. Furthermore, it is unclear if such a screen would detect
only a subset of PE cases initiated by a specific etiological fac-
tor, and be blind to other etiological triggers.
Early detection of PE – the current status – is there a
need for new additional biomarkers?
Numerous studies confirmed the high performance of the sFlt-
1/PlGF ratio in the second and third trimester of preg-
nancy [16,108–112]. The ratio can be used in asymptomatic
women at high risk of developing PE, as well as in women
with signs and symptoms of PE [109–111]. So far, sFlt-1/PlGF
ratio has not been evaluated as a screening test for PE in wide-
spread clinical practice. Furthermore, the timeframe of the use
of the sFlt-1/PlGF ratio lies after the established time point of
starting low-dose aspirin (before 16th week of gestation) to
have a beneficial effect on the occurrence of early-onset PE
[6,113,114].
There is good evidence that a combination of different bio-
and ultrasound-markers pregnancy-associated plasma protein A,
PlGF, mean maternal arterial pressure (MAP), with the pulsa-
tility index (PI) of the uterine arteries has a detection rate of
93% for early-onset PE and 61% for cases before 37th week of
gestation, at a false-positive rate (FPR) of 5% [115].
However, because the majority of the PE cases are consid-
ered as late-onset forms, there is an urgent need for additional
biomarkers [37,38].
Development of new biomarkers for early detection of
PE – the issue of early versus late events
A major gap in our understanding of PE is what the initiating
lesions are [7,9]? Indeed, it may be that the key events triggering
the cascade leading to PE occur so early in pregnancy and are
so subtle that they are not readily detectable by current tech-
nologies. This renders the quest for biomarkers suitable for
detection of at-risk pregnancies at the integrated 11- to
13-week screen difficult. This deficit becomes evident when
examining the utility of current screening tools, such as those
implicated in the angiogenic imbalance, where significant
changes in sFlt-1 levels are only noted after 20 weeks of gesta-
tion [112]. It is also evident based on publications to date that
changes in the innate immune system, such as neutrophil [19,66],
or complement activation [70], are likely to be mostly late events
in the etiological cascade, and may not be evident in the late
first trimester of at-risk pregnancies.
Furthermore, the functional role of biomarkers included in
current or suggested screens such as a-fetoprotein, human chori-
onic gonadotropin, pregnancy-associated plasma protein A,
inhibin-A, activin-A, pentraxin 3 (PTX3) or P-selectin in PE eti-
ology is unknown or questionable. It is perhaps for this reason
that a list of over 70 unrelated biochemical analytes has been
proposed for inclusion in future screening assays, which would
not be feasible in clinical practice [115]. It is, therefore, a tenet of
several researchers in the field that the development of effective
screening markers or therapeutic approaches will only be possible
once a more complete understanding of the biological cascade
leading to the development of manifest PE is known [6,7].
Development of new biomarkers – which approach is
best?
Due to this knowledge deficit concerning the key initiating
steps driving the development of PE, it is unclear what the best
strategy for the development of new markers should be [116,117].
It is, however, evident that by examining affected placentae but
whatever sophisticated molecular biological means, that this
will only lead to an increasingly intimate knowledge of the
final state of the disorder, but not provide more than an
inkling of initiating steps. The same caveat would appear to
exist for maternal blood transcriptomic analyses, as most PE-
specific changes have been seen so far as a relatively late event.
As such, any potential biomarkers obtained by these means will
largely only be useful for the detection of imminently threaten-
ing PE cases [6,7].
Since it is not possible to readily obtain placental material
early in gestation, it has been suggested to establish a biobank
of villi obtained by CVS for the detection of fetal aneu-
ploidy [118,119]. As this is usually carried out at the end of the
first trimester, this could be an ideal source of vital material.
Samples obtained from pregnant women who develop PE
could then be compared with those with normal outcome.
Although to be lauded such an approach is hampered by the
low incidence of PE, especially that of ePE, thereby necessitat-
ing a very large biobank of material which is not readily attain-
able. Furthermore, due to the high sensitivity of current
screening programs for fetal aneuploidy, very few of the CVS
samples will have a normal fetal genotype [120].
Since most biomarkers used in clinical screening are blood
based, it has been suggested that maternal plasma obtained in
the first trimester could be a good source of starting material [116].
This could be examined by quantitative proteomic technologies
using isobaric labeling isobaric tags for relative and absolute
quantification, whereby patient samples are labeled with one set
of tags and the reference samples with another discrete
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set [116,121,122]. This permits highly precise quantitative compari-
son of specific peptide concentrations between cases and controls
by mass spectrometry. By such means, an examination of first
trimester maternal plasma samples obtained from pregnant
women who subsequently developed PE revealed significant
quantitative differences in 10 peptides, including fibronectin,
angiotensinogen, galectin-3-binding protein, plasminogen and
transferrin [121]. It is noteworthy that some of these potential bio-
markers were corroborated by a parallel proteomic study using a
different proteomic methodology, 2D difference gel electropho-
resis [THAN NG ET AL., UNPUBLISHED DATA]. It is currently not clear how
useful or specific these markers are for early PE detection. Since
a similar analysis for the development of DS screening markers
detected known screening analytes such as a-fetoprotein and
human chorionic gonadotropin, it would appear that the isobaric
tags for relative and absolute quantification approach may prove
to be a useful tool [116,121,122].
Unfortunately, of the large number of proteomic studies car-
ried out for PE biomarker discovery, only a few of these
focused on maternal blood samples obtained prior to onset of
symptoms, and of these only two examined first trimester
samples [123–125]. There is thus a huge need for well-designed
clinical studies geared toward biomarker discovery, such as the
EU-funded Improved Pregnancy Outcomes by Early Detection
(IMPROVED) study [126].
A major concern with the detection of new proteomic bio-
markers is the validation of their usefulness [116]. For this pur-
pose, it would be the best to use methods developed for systems
biology analyses, such as selective reaction monitoring or its
further bioinformatics development of SWATH MS [127,128].
Development of new biomarkers – can a translational
approach be used?
Since access to human material indicative of the early initiating
lesion is high or impossible to obtain, the question arises
whether it is not possible to use an animal model system to
gain insight into these key steps [129–133]. The main issue with
commonly used rodent model systems, such as the mouse, is
that the placenta is very different from that of humans, espe-
cially with regard to spiral artery modification [51,130]. On the
other hand, even though evidence of such features may be pres-
ent in guinea pigs, this model system is hampered by the lack
of specific reagents, especially antibodies. Nevertheless, the
murine hemochorial placenta may be useful to examine certain
facets, especially as the placental tissue is in direct contact with
maternal immune cells [134]. As such, a translational approach
may be possible for the study of PE [129], especially when rely-
ing on a systems biology approach [133].
In this context, it has been shown that factors contributing to
an angiogenic imbalance in PE such as sFlt-1 or endoglin can
be used to induce PE-like symptoms in mice or rats [135–138].
Furthermore, activation of the complement cascade by either
anti-phospholipid antibody treatment, induction of ischemia or
genetic knock-out of the C1q gene has similarly been shown to
induce PE-like conditions in mice or rats [107,139,140].
It has further been shown that the CBA/J x DBA/2 mouse
model of recurrent miscarriages shares a number of PE-like fea-
tures, including proteinuria, endothelial cell damage, increased
sensitivity to angiotensin II and elevated plasma leptin lev-
els [129]. Akin to human PE, this spontaneous mouse model
involves an imbalance in angiogenic factors, including VEGF
and sFlt-1. Its clinical usefulness is underscored by the observa-
tion that treatment with pravastatin restored the angiogenic
imbalance, and ameliorated glomerular damage, thereby paving
the way for the recent similar treatment of a PE patient with
anti-phospholipid syndrome.
Animal models have also been developed to test the func-
tional role of proteins identified in proteomic screens such as
transthyretin, the serum level of which is reduced in PE [141].
In a humanized murine model for PE, application of exoge-
nous transthyretin leads to a reversal of PE symptoms, includ-
ing proteinuria, elevated BP, glomerular endotheliosis and
production of anti-angiogenic factors [141]. These findings lead
to the suggestion that transthyretin can serve as a new bio-
marker for PE [142].
In a recent publication, it has been shown that mice lacking
the tryptophan catabolizing enzyme IDO develop symptoms
consistent with those of PE [143]. IDO has previously been sug-
gested to play a key role in maintaining fetomaternal tolerance
by regulating maternal T-cell activity [24]. A decrease in its
activity has also been implicated in development of PE [144].
A further interesting report indicates that inappropriate
inflammation, induced by low-dose lipopolysaccharide in preg-
nant rats, inhibits spiral artery remodeling, thereby leading to
IUGR and PE-like features [145], which are mirrored by altered
placenta morphometrics [146].
Although these results may appear exciting or encouraging,
the fundamental problem with such animal models is that it is
unclear how they compare the early initiating lesions leading to
PE, which is considered to be a disease mainly of humans and
is very rarely observed in a few evolutionarily closely related
anthropoid primates [147,148]. Consequently, their analysis may
once again simply increase our understanding of late events
that appear imminently prior to clinical symptoms. A further
concern is that they may lead to a skewed appraisal of the
events occurring in humans, as seems to be the case in a com-
plex comparative murine-human translational proteomic analy-
sis, in which no evidence of inflammation was obtained [103].
Early- versus late-onset PE – which disorder do we
need to detect?
When considering the development of biomarkers for the early
(first trimester) detection of PE, it is important to consider
whether the emphasis will be placed on either ePE or lPE [1,6].
This deliberation should include an analysis of the difference
in incidence between the two forms, the associated fetomaternal
morbidity/mortality and the possibility of therapeutic interven-
tion [1,6].
A recent examination of 607,120 singleton deliveries indi-
cated that the incidence of ePE was 0.3%, while that for lPE
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was 2.7% [37,38]. ePE was associated with a higher rate of
maternal mortality (42.1/100,000 deliveries), while that of lPE
(11.2/100,000 deliveries), albeit this latter was still significantly
higher than in normal healthy pregnancies (4.2/100,000 deliver-
ies) [37,38]. Furthermore, maternal morbidity while higher in
ePE than lPE cases was still higher in the latter than in uncom-
plicated pregnancies [37,38]. This confirms previous observations
that cases with lPE need optimized care, and that failure to do
so can have severe consequences, especially in rural settings [39].
It would, therefore, appear that under ideal settings, that
newly developed tests would detect both PE forms with equal,
or similar, efficacy. An analysis of current attempts to achieve
this, however, indicates that such a goal may be difficult to
achieve, in that pregnancies at-risk for ePE are detected with
much greater efficacy than those that develop lPE [115,149]. In
this context, recent reports suggest that 95% of cases with ePE
can be detected with a FPR of 10%, while approximately only
50–70% of cases with lPE with the same FPR [115]. Since the
ability to detect lPE decreases with increasing gestational age of
onset, these data are once again indicative of multiple, shared
and disproportionate initiating etiological lesions leading to the
development of ePE and lPE.
For this reason, it has been suggested to split PE screening
into two arms, an early phase incorporated into the 11- to
13-week integrated test, and second screen carried out at
30–33 weeks to detect cases with lPE [1]. The latter test would
rely on current screens assessing an imbalance in angiogenic
factors (PlGF/sFlt-1), which should detect all cases with lPE
for a FPR of 5% [1].
Expert commentary
A major facet to consider before initiating the chase to develop-
ment of new biomarkers for PE detection is what the uptake of
current screens into widespread clinical practice has been [150].
Following the observation that an imbalance in angiogenic fac-
tors (PlGF/sFlt-1) precedes the development of PE [112], a
number of very large-scale studies have been carried out to
examine the usefulness of this approach. This included studies
carried out under the auspices of the NIH, WHO as well as
several carried out in conjunction with leading pharmaceutical
companies [108–111]. These studies have clearly shown that a
quantitative assessment of these factors has a very high predic-
tive value for detecting the onset of PE post 34 weeks of gesta-
tion [110]. Indeed, it has also been shown that they can be
useful to detect cases of PE that develop during triage [111].
Despite these promising results and generally low cost of the
ELISA assays, it is astounding that no published report exists
to date documenting clinical implementation.
This is in widespread contrast to the rapid uptake of newly
developed non-invasive prenatal testing assays examining feto-
maternal cfDNA by complex next-generation sequencing tech-
nologies, where a constantly high demand exists [151,152]. This is
all the more astonishing granted the high costs of these tests,
which are frequently not reimbursed by healthcare
insurers [153].
It would thus appear that the detection of a DS fetus has a
higher priority in our society than the detection of a grievous dis-
order associated with high rates of maternal mortality. Further-
more, it should be noted that PE is associated with an increased
risk of severe cardiovascular and metabolic complications for
both mother and child later in life, thereby placing a considerable
burden on already stretched healthcare budgets [154]. Under these
conditions, it seems invidious to suggest that there are ethical
concerns with the implementation of new PE screens [155], rather
it would appear unethical to ensure the widespread implementa-
tion of such assays, especially in developing countries where
access to high-quality care is limited [10,39].
Five-year view
An a priori requirement for the development of new bio-
markers for the early detection of PE is a solid understanding
of the key initiating placental lesions [6,7]. This will require a
concerted multicenter or even multinational effort harnessing a
wealth of experience from a variety of scientific and clinical dis-
ciplines. The newly established NIH Human Placenta Project
is a step in the right direction [156].
Another requirement is to ensure the efficacious translation
of current laboratory developed assays, such as those for PlGF/
sFlt-1, which have been shown to be reliable and robust into
widespread clinical practice. This will help in assisting the simi-
lar transfer of the next generation of assays.
In order to achieve this, the perception of PE, its devas-
tating consequences and the hope of new developments need
to be firmly communicated to the general public. Such a
lobbying force will also ensure adequate funds are available,
a vital requirement in scientific field known to be under-
resourced financially and in dire need to new effective
therapies [92,157].
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Key issues
. Current attempts at the early detection of preeclampsia (PE) via first trimester screening systems, preferentially detect cases with early-
onset PE rather than late-onset PE.
. This may reflect upon fundamental etiological differences between these two forms of PE.
. The etiology ePE appears to involve a distinct early placental lesion that is the key driving force for the development of PE symptoms,
with little or no contribution by secondary inflammatory incidents.
. Although significant when compared with control pregnancies, the placental lesion in lPE serves in a priming capacity, rendering the
maternal innate immune system highly susceptible to secondary inflammatory signals (e.g., obesity), which then triggers the develop-
ment of clinical symptoms.
. Deficiency in scavenger molecules, such as seleno-proteins or A1M may contribute to increased susceptibility to secondary inflammatory
signals in lPE. These form the basis for novel therapies.
. Animal models and systems biology approaches could be exploited to obtain clearer insight into etiological differences between ePE and
lPE. These include studies on the role of complement activation, therapeutic use of A1M to counter PE symptoms, or data indicating
that inflammation during early placentation hinders spiral artery modification.
. These fundamental etiological differences between ePE and lPE may, however, hinder the reliable detection of lPE using first trimester
screening, or render it impossible.
. The development of reliable point-of-care tools for the imminent detection of lPE in tertiary rural settings would be a life-saver and
should not be neglected.
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